Can Wegovy cause pancreatitis, and how serious is the risk?

Is pancreatitis a real risk with Wegovy, or just a label warning?

It is a real risk, not a box-ticking formality. Pancreatitis (inflammation of the pancreas) has been reported in people taking semaglutide, and the MHRA's January 2026 Drug Safety Update confirmed that all GLP-1 receptor agonists, including Wegovy, carry this as a known safety signal. That does not mean it is common. In the clinical trial programme, acute pancreatitis was infrequent; most people taking Wegovy do not experience it. But infrequent does not mean ignorable, because when pancreatitis does occur it can be severe and requires prompt treatment.

The biological reason the risk exists is that semaglutide activates GLP-1 receptors, some of which are present in pancreatic tissue. This affects how the pancreas secretes enzymes and hormones. For most people that process runs uneventfully. In a small number, inflammation develops. Pre-existing conditions (a history of pancreatitis, gallstones, or very high triglyceride levels) are factors a prescriber will weigh when assessing suitability. The detailed look at whether Wegovy can give you pancreatitis covers those individual risk factors in more depth.

If you have had pancreatitis before, that history matters. Tell the prescriber at consultation. It does not automatically rule out treatment, but it changes the clinical conversation significantly.

What does pancreatitis actually feel like — and how is it different from ordinary Wegovy nausea?

This is the question our prescribers hear most often when the topic comes up, and it is worth answering precisely. Ordinary Wegovy-related nausea tends to be diffuse, is most noticeable after starting or increasing the dose, and typically settles within a couple of weeks. It rarely gets worse over hours. The guidance on eating to reduce Wegovy nausea is useful for that kind of everyday discomfort.

Pancreatitis pain is different in character. It tends to be severe and persistent rather than mild and fleeting. The classic pattern is pain that starts in the upper abdomen and radiates through to the back, dull, relentless, often made worse by eating or lying flat. It may come with vomiting that does not ease the pain the way ordinary nausea does. Fever can develop as inflammation escalates.

A quick self-check you can do right now: press gently on your upper abdomen just below your ribcage. Ordinary bloating from a big meal is uncomfortable but vague. True pancreatitis tenderness is sharp and localised, and pressing makes it worse. That difference is a useful prompt, if you are unsure, err on the side of seeking help rather than waiting it out.

For context on how quickly symptoms can appear after a dose change, our page on how quickly Wegovy can cause pancreatitis covers the reported timelines from the literature.

When should you get medical help, and what should you do first?

If you develop severe, persistent abdominal pain (especially pain reaching into your back) while taking Wegovy, get medical help the same day. Call 111 if you are unsure how urgent it is. Go to A&E if the pain is severe or you are vomiting repeatedly and cannot keep fluids down. Do not wait for your next scheduled appointment and do not simply stop your injections without speaking to a clinician first.

Tell the treating team that you are on semaglutide (Wegovy). That context matters for the differential diagnosis and guides what tests they order. Blood tests measuring pancreatic enzymes (amylase and lipase) confirm or rule out pancreatitis quickly.

After you have been assessed and are stable, please report your experience through the MHRA Yellow Card scheme. Patient reports are how regulators spot patterns in real-world use that clinical trials cannot always capture. It takes a few minutes and genuinely contributes to the safety evidence base for everyone who takes these medicines.

If your episode is confirmed as pancreatitis, restarting Wegovy will be a clinical decision made carefully with your prescriber, not something to navigate alone. The full pancreatitis and Wegovy resource covers what typically happens next.

How can you reduce your risk before and during treatment?

There is no guaranteed way to prevent pancreatitis, but there are steps that lower your exposure to the modifiable risk factors. The NHS semaglutide patient page advises telling your prescriber before starting if you have had pancreatitis, gallbladder disease or high triglycerides. Those disclosures shape whether treatment is suitable and at what pace titration should proceed.

During treatment, following a low-fat diet reduces strain on the pancreas in general. High-fat meals are a known trigger for pancreatitis regardless of semaglutide, and Wegovy already slows gastric emptying, combining both stressors is worth avoiding. Staying well hydrated helps too, particularly during the early weeks when nausea and reduced appetite can make it easy to drink less than you should.

Our guide to preventing pancreatitis on Wegovy and the companion piece on practical avoidance strategies go into more granular detail on diet and monitoring habits. More broadly, the safest foundation for any treatment decision is a thorough clinical assessment, our prescribers at nume's clinical team discuss side-effect risk, personal history and suitability as a standard part of every consultation. If this page has raised questions you would like answered before you start, starting a free consultation is the right next step.